NCT07398261进行中（未招募）3 期
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 151
- 试验地点
- 1
- 主要终点
- Partial or complete response
研究概览
简要总结
This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •- Non-monosymptomatic nocturnal enuresis
排除标准
- •monosymptomatic nocturnal enuresis
研究组 & 干预措施
Mirabegron 25 mg
Active Comparator
Patients received mirabegron 25 mg orally
干预措施: Mirabegron 25 MG (Drug)
no intervention
No Intervention
no intervention
结局指标
主要结局
Partial or complete response
时间窗: 18 months
次要结局
未报告次要终点
研究者
Mohammed Ali abdelghaffar
Assistant lecturer of urology
Menoufia University
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionUreteral CalculiNCT07310797Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation500
招募中
2 期
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trial2024-511964-95-00Azienda Ospedale-Universita Padova110
尚未招募
不适用
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder CancerNCT07279597Tongji Hospital45
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic ArthritisNCT07315061InventisBio Co., Ltd222
招募中
不适用
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerNCT07356531JIANGSU SHENMING Medical Technology CO., Ltd216